Evaluation of the Effect of Combination Therapy on Treatment of COVID-19: A Cohort Study

Ghazale, AmirHosein and Ghazvini, Ali and Ghanei, Mostafa and Vahedi, Ensieh and Omidian, Shideh and Mozafari, Abolfazl and Rezapour, Mohammad and Rastgoo, Nafiseh and Movaseghi, Fatemeh and Mansouri, Fateme and Zohal, Mohammadali and Gheraati, Maryam and Saadat, Seyed Hassan and Goodarzi, Hassan and Gholami Fesharaki, Mohammad and Dehghan Banadkooki, AmirMohammad and Saloo, Shahrzad and Salou, Hesamodin (2021) Evaluation of the Effect of Combination Therapy on Treatment of COVID-19: A Cohort Study. IRANIAN RED CRESCENT MEDICAL JOURNAL.

[img] PDF
Download (497kB)


Background: COVID-19 is a new disease for which a definitive treatment has not yet been proposed. Objectives: The present study aimed to investigate the effect of combination therapy on the treatment of COVID-19 due to the importance of finding an appropriate treatment for this epidemic disease. Methods: This two-center cohort study included 175 confirmed COVID-19 inpatients at two medical centers designated for the treatment of COVID-19 patients in Qom and Qazvin, Iran. In this study, four different groups of drug regimens were studied which included G1 (azithromycin, prednisolone, and naproxen), G2 (lopinavir/ritonavir, azithromycin, naproxen, and prednisolone), G3 (hydroxychloroquine, azithromycin, naproxen, and prednisolone), and G4 (levofloxacin, vancomycin, hydroxychloroquine, and oseltamivir). It should be noted that G1, G2, G3, and G4 treatment regimens were used on 48, 39,30, and 77 patients, respectively. Results: The study participants included 175 confirmed COVID-19 patients with mean±SD age of 58.9 ±15.1 years, out of whom 80 (46%) patients were male and the rest were females. The results indicated that the hospital stay period was significantly shorter in the G1 compared to other groups (G1:5.9±2.4, G2:8.1±4.2, G3: 6.3±1.7, and G4: 6.4±2.9; [P-value=0.008]). It should be noted that pulse rate, oxygen saturation, hemoglobin, and platelet count (PLT) changed significantly during the study in four treatment groups; however, a significant change in temperature, creatinine, and white blood cell (WBC) was observed only in G3, G4, and G1 groups, respectively. The number of ICU admissions and deaths were not statistically significant among the patients who received the four treatment regimens (P=0.785). Based on the results, the history of ischemic heart disease, baseline oxygen saturation, WBC, neutrophil, lymphocyte count, and C-reactive protein (CRP) are the risk factors for the prolonged hospital stay in COVID-19 patients. Conclusion: The obtained results in this study indicated that the combination of azithromycin, prednisolone, and naproxen is the most effective regimen for the treatment of COVID-19, compared to three other combination treatment regimens. Keywords: Anti-inflammatory drugs, Antiviral drugs, Combination therapy, Corticosteroid, COVID-19, Immunomodulators drugs

Item Type: Article
Subjects: R Medicine > R Medicine (General)
Divisions: University Portal > research center > Metabolic
Depositing User: pr Metabolic diseases research
Date Deposited: 14 Nov 2022 10:13
Last Modified: 14 Nov 2022 10:13
URI: http://eprints.qums.ac.ir/id/eprint/12208

Actions (login required)

View Item View Item